D IABETIC NEUROPATHY (DN) is a common compli-
cation of type 1 and 2 diabetes, and affects approximately 20% of adult diabetic patients (1) . Patients with DN experience a progressive loss of sensation following a "stocking and glove" pattern, resulting from length-dependent axonal loss (2) . Clinical trials have failed to demonstrate the effectiveness of any drug treatment in stabilizing or improving nerve function (1) . In the absence of promising results from the currently available drugs and drug targets, new classes of drugs are being evaluated for the treatment of DN.
Thiazolidinediones (TZDs) are potent insulin sensitizers used to treat type 2 diabetes and insulin-resistant type 1 diabetes (3). TZDs were first identified as insulin-sensitizing agents by Chang (4, 5) and Fujita et al. (6) , who evaluated their antidiabetic effects in mouse models of type 2 diabetes and a rat model of type 1 diabetes. The mechanism of this antidiabetic activity was determined to be activation of peroxisome proliferator-activated receptor (PPAR)-␥, a transcription factor (TF) in the nuclear receptor family (7) . Although other PPAR TFs are ubiquitously expressed, PPAR-␥ is specific to adipose tissue, kidney, liver, and Schwann cells (8, 9) . Microarray studies of gene regulation by TZDs found that they alter steady-state mRNA levels of several hundred genes, primarily those involved in glucose and lipid metabolism (10) .
Recent evidence suggests that TZDs reduce the development of diabetic complications independent of insulin sensitization. TZD treatment reduces the formation of atherosclerotic plaques (11) , a macrovascular complication, and also reduces oxidative stress and the inflammatory response (12) , two mechanisms of microvascular complications. TZD effects on oxidative stress are attributable to a number of potential causes, including altered expression of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and improvement of mitochondrial health (13, 14) . Two studies were performed demonstrating that TZDs slow or prevent the development of neuropathy in models of type 1 diabetes. In streptozotocin (STZ)-treated rats, troglitazone protects against nerve conduction velocity (NCV) slowing, and maintains normal myelinated fiber architecture and number (15) . Pioglitazone also has neuroprotective effects on NCV and reduces macrophage infiltration in the sciatic nerve (8) . These improvements in the DN profile of the diabetic rats cannot be explained by insulin sensitization and are due to some other effect of TZDs. Troglitazone is an innate antioxidant as well as glitazones (16) , and may reduce oxidative stress independent of TF activation. No such alternative mechanism is known for pioglitazone, and changes in protein expression suggest that a gene regulatory mechanism was activated (9) . A systems biology approach may elucidate this gene regulatory mechanism, but a rat model of diabetes was used by both research groups, which is nonideal for gene expression profiling.
Although TZDs have significant promise in the treatment of DN, their side effects may limit their usefulness (17) (18) (19) . Due to the heterogeneous complications of members of the
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TZD family, we hypothesize that the beneficial effects of TZDs on diabetic complications are independent of the mechanisms that cause adverse effects. Screening the gene expression patterns induced in the nerve by PPAR-␥ agonist activity may allow us to separate these positive and negative effects, and identify regulatory mechanisms that affect the development of DN. We examined changes in gene expression in sciatic nerves of mice with STZ-induced diabetes and TZD treatment to define downstream transcriptional responses. Using systems biology, we inferred likely regulatory mechanisms based on those changes. Such regulatory mechanisms constitute starting points for more specific drug target development with the potential to separate the beneficial and harmful effects of TZDs. A TZD with no known innate antioxidant capacity, rosiglitazone (Rosi), was chosen as the treatment to minimize the potential confounding effects on oxidative stress. Gene expression changes were measured using Affymetrix microarrays (Affymetrix Inc., Santa Clara, CA), revealing that novel transcriptional control sequences are present in genes strongly correlated with DN.
Materials and Methods Mice
DBA/2J mice (stock no. 000671) were purchased from The Jackson Laboratory (Bar Harbor, ME). Breeding colonies established at the University of Michigan provided the animals used in this study. Mice were housed in a pathogen-free environment, and cared for following the University of Michigan Committee on the Care and Use of Animals guidelines. Mice were fed powdered mouse chow (Purina 5001; Purina Mills, LLC, St. Louis, MO).
Induction of diabetes and Rosi treatment
Four treatment groups were defined: control (n ϭ 17), diabetic (n ϭ 15), control plus Rosi (n ϭ 18), and diabetic plus Rosi (n ϭ 13). Diabetes was induced by low-dose STZ treatment (40 mg/kg for 5 d) when the animals reached a weight of 22 g (ϳ10 wk old). Two weeks after STZ treatment, or the equivalent time point for control mice, Rosi (3 mg/kg orally⅐d) was given in Nutra-Cal (Vetoquinol USA, Buena, NJ) to half of the diabetic and control animals. To increase survival, diabetic and diabetic plus Rosi mice were implanted with a sustained release insulin implant (Linbit for mice 0.1 U insulin/d/implant; LinShin Canada, Inc., Scarborough, Toronto, Ontario, Canada) 10 wk after STZ treatment. The second and third implants were inserted after 15 and 20 wk diabetes.
Measurement of blood glucose and glycosylated hemoglobin (GHb)
Fasting blood glucose levels were measured every 4 wk to document the persistence of diabetes. After a 6-h fast, one drop of tail blood was analyzed using a standard Glucometer (OneTouch; LifeScan Inc., Milpitas, CA). At 24 wk, GHb was measured using the Helena Laboratories Test Kit, Glyco-Tek Affinity Column Method (Helena Laboratories Corp., Beaumont, TX).
Thermal latency
Mice were placed in a plantar test apparatus (model 336TG; Life Sciences, Woodland Hills, CA) on a warm (32 C) glass plate and allowed to habituate for 10 min. An adjustable red light emitter (range 60 -170 C) was maneuvered under the hind paw, and the time of activation of the beam to the time of paw withdrawal was recorded. The light source was set at 25 C and the temperature increased to 70 C over the course of 10 sec.
Nerve conduction studies
NCVs were recorded as previously described (20, 21) . For the sciatic nerve, the recording electrodes were placed in the dorsum of the foot, and the stimulating electrodes at the knee and sciatic notch. For the sural nerve, the anode was placed on the third toe of the foot, and the cathode was placed on the heel of the foot. The cathode and anode were placed 5-mm apart. The frequency band was inclusive of two, 10 Hz muscle potential recordings (orthodromic, motor) and 10, 2-Hz potential recordings (antidromic, sensory).
Tissue harvest
Twenty-four weeks after induction of diabetes, mice were euthanized by sodium pentobarbital overdose and tissues harvested as previously described (20, 21) . A blood sample (50 l) was collected for measurement of GHb [see Measurement of blood glucose and glycosylated hemoglobin (GHb) ]. The left sciatic nerve was dissected and stored in 30 l RNA later (Ambion, Inc., An Applied Biosystems Business, Austin, TX) for gene expression analysis. The right sciatic nerve was dissected and immediately submerged in ice-cold antioxidant buffer, rapidly frozen by immersion in liquid nitrogen, and stored at Ϫ70 C for quantification of end products of oxidative damage.
Oxidative stress measures
Five samples from each experimental group were analyzed as previously described (22) (23) (24) . Tissue was homogenized at 4 C in buffer [100 m diethylenetriaminepentaacetic acid, 50 m butylated hydroxytoluene, 1% (vol/vol) ethanol, 10 mm 3-amino-1,2,4-triazole, and 50 mm sodium phosphate buffer (pH 7.4)], frozen, and thawed. Protein was precipitated with ice-cold trichloroacetic acid (10% vol/vol), collected by centrifugation, washed with 10% trichloroacetic acid, and delipidated twice with water/methanol/water-washed diethyl ether (1:3:7 vol/vol). Isotopically labeled internal standards were added, and samples were hydrolyzed in 4 n methane sulfonic acid at 110 C for 24 h under argon as described previously (24) . Hydroxyoctadecadienoic acids (HODEs) were quantified by reverse-phase C-18 HPLC analysis of triphenylphosphine-reduced lipid extracts after base hydrolysis. The protein content of tissue pellets was determined by a modified Lowry protein assay using BSA as a standard (23) .
Amino acids were isolated from the acid hydrolysate using a solidphase C-18 column (Supelclean SPE; Supelco Inc., Bellefonte, PA). Analyses of the dabsylated derivatives of tyrosine and O,OЈ-dityrosine were performed by reverse-phase HPLC (JASCO HPLC; JASCO, Essex, UK; Column; and Beckman ODS Ultrasphere C-18 column; Beckman Coulter, Inc., Fullerton, CA) as described previously (22) . The identity of the compounds was confirmed by identical retention times of authentic O,OЈ-dityrosine and tyrosine. Quantification was performed by constructing standard curves using authentic O,OЈ-dityrosine and tyrosine.
RNA preparation
Total RNA was isolated using a commercially available silica gelbased isolation protocol (RNeasy Mini Kit; QIAGEN, Inc., Valencia, CA), including an on-column deoxyribonuclease digestion following the manufacturer's protocol. RNA quantity and quality were measured by microfluid electrophoresis using the RNA 6000 Pico LabChip on a 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA).
Affymetrix microarrays
Five samples from each experimental group were analyzed for gene expression. Of total RNA, 75 ng was amplified and biotin labeled using the Ovation Biotin-RNA Amplification and Labeling System (NuGEN Technologies, Inc., San Carlos, CA) according to the manufacturer's protocol. Amplification and hybridization were performed by the University of Michigan Comprehensive Cancer Center Affymetrix and Microarray Core Facility (University of Michigan, Ann Arbor, MI) using the GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Intensities of target hybridization to the respective probe features on the chip were detected by laser scan of the array. Image files were generated by Affymetrix GeneChip software (MAS5). Microarray data are available via the Gene Expression Omnibus, accession no. GSE11343.
Real-time RT-PCR
The expression of eight regulated genes from the microarray was confirmed by real-time RT-PCR performed on five independent samples from each experimental group. The amount of mRNA isolated from each sciatic nerve was first normalized to an endogenous reference [TATA box binding protein; ⌬ cycle threshold (C T )] and then relative to a control group (⌬⌬C T ), and was expressed as 2 Ϫ⌬⌬C T .
Data analysis
The Affymetrix CEL files were analyzed using the National Center for Integrative Biomedical Informatics (http://portal.ncibi.org/gateway/) GenePattern server. The samples were Robust Multichip Average normalized using the BrainArray Custom CDF Mm430A2_Mm_ENTREZG version 9 (http://brainarray.mbni.med.umich.edu/brainarray/default. asp) (25) and log2 transformed. A Student's t test, CyberT False Discovery Rate (FDR) (26) , and fold change were calculated. Standard libraries from the bioconductor project (www.bioconductor.org), the R project (www.r-project.org), and GenePattern (www.broad.mit.edu/ cancer/software/genepattern/) were used. The Database for Annotation, Visualization and Integrated Discovery (DAVID) 2007 (27) functional annotation clustering tool was used to attribute functional annotation to the lists of significantly regulated genes.
Data analysis for phenotypical and oxidative stress data was performed using GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, CA). When performing comparisons across more than two groups, a one-way ANOVA test was performed, and Bonferroni corrected P values were used. If the multiple group comparison did not reach significance, the directed hypothesis that diabetic mice develop complications was tested using a one-way t test.
TF binding sites
The Genomatix Transcription Factor binding motif database was used to search for TFs common to regulated genes. Only sequences with an empirically verified transcript were searched. Five hundred base pairs upstream of the first transcription start site (TSS) and 100 bp downstream of the last TSS were designated as the promoter region. FrameWorker was used to identify new transcription minding motifs, with a threshold of 40% genes containing the motif and an intersite variability of 20 bp or less. ModelInspector was used with the default settings to search for previously characterized TF binding modules, with queries limited to the top strand.
The National Center for Integrative Biomedical Informatics GenePattern server was used to run the Broad Institute Gene Set Enrichment Analysis (GSEA) module (version 1) for GenePattern 3.0 (28). Default settings were used aside from increasing the permutation count to 1000 and disabling the probe set collapsing option.
Results

Fasting blood glucose, GHb
Fasting blood glucose was significantly elevated in diabetic mice 6, 12, 16, 20, and 24 wk after STZ (P Ͻ 0.001). GHb was also significantly increased after 24 wk, indicative of prolonged hyperglycemia (P Ͻ 0.001). Diabetic mice lost a significant amount of weight compared with control mice (P Ͻ 0.001). Rosi treatment had no significant effect on blood glucose, GHb, or weight loss in the DBA/2J mice (Table 1) . There is no evidence that the levels of insulin provided to the mice resolved their diabetes or that Rosi treatment enhanced the efficacy of the insulin supplement.
Neuropathy DN in the DBA/2J mice was assessed by thermal latency in the hind paw, and NCV in the sciatic and sural nerves. Thermal latency was significantly increased after 24 wk diabetes (control ϭ 6.3 Ϯ 1.0 sec, diabetic ϭ 11.1 Ϯ 0.8 sec; P Ͻ 0.001; Fig. 1 ). Despite maintaining the same mean blood glucose as diabetic mice (Table 1) , the diabetic plus Rosi mice had significantly lower thermal latency (diabetic plus Rosi ϭ 7.6 Ϯ 1.2; P Ͻ 0.001). Sensory and motor NCVs were measured in the sural and sciatic nerves. Sural NCV was decreased by 14% in diabetic mice (control ϭ 23.7 Ϯ 3.5 m/sec, diabetic ϭ 20.3 Ϯ 3.2 m/sec; P Ͻ 0.05), whereas sciatic NCV was decreased by 24% in diabetic mice (control ϭ 45.5 Ϯ 3.9 m/sec, diabetic ϭ 34.4 Ϯ 7.1 m/sec; P Ͻ 0.01). Although there was a trend toward reduced impairment of NCV after Rosi treatment, it did not reach significance.
Oxidative stress measures
Oxidative stress is a major mechanism of hyperglycemiainduced DN in humans, particularly through the oxidation of proteins and lipids. To determine whether oxidative stress was elevated in the DBA/2J-STZ mice, we quantified levels of protein-bound O,OЈ-dityrosine and HODE in the nerve. Dityrosine was significantly increased by diabetes (control ϭ 68.4 Ϯ 15.0 mol/mol tyrosine, diabetic ϭ 131.9 Ϯ 17.9 mol/mol; P Ͻ 0.001). This effect was reduced significantly by treatment with Rosi (diabetic plus Rosi ϭ 97.3 Ϯ 10.1 mol/mol; P Ͻ 0.01). HODE in the nerve was also significantly increased by diabetes (control ϭ 259.2 Ϯ 47.4 pmol/mg protein, diabetic ϭ 465.4 Ϯ 154.7 pmol/mg; P Ͻ 0.05), and the effect was attenuated by Rosi (diabetic plus Rosi ϭ 255.2 Ϯ 31.1 pmol/mg; P Ͻ 0.05). Rosi treatment did not affect dityrosine or HODE in nondiabetic DBA/2J mice.
The correlation between thermal latency and dityrosine was found to be highly significant (r ϭ 0.80; P Ͻ 0.001), as was the correlation between thermal latency and HODE (r ϭ 0.71; P Ͻ 0.001). We hypothesized that Rosi activates cellular mechanisms of free radical management. We tested this hypothesis by analyzing gene expression patterns in DBA/2J mice.
Gene expression changes in diabetes
Affymetrix Mouse Genome 430 2.0 microarrays were used to measure the expression of 12,150 genes in the sciatic nerve (n ϭ 5 mice per group). One array of a control animal did not pass quality control and was excluded from further analysis (data not shown). Changes in expression between groups Final weight was reduced in diabetic mice (P Ͻ 0.001); 20-wk blood glucose and final GHb were increased (P Ͻ 0.001).
were tested by a t test and the CyberT FDR (26) . Genes with both a P value and FDR less than 0.05 were considered differentially expressed genes (DEGs). A total of 526 DEGs was found between control and diabetic, 318 between diabetic and diabetic plus Rosi, and 345 between control and control plus Rosi. The DEGs between control and diabetic mice were clustered into functional categories using the DAVID functional annotation tool (Table 2) . Some diabetic DEGs were also significantly regulated by Rosi treatment. There were 15 genes down-regulated by diabetes and upregulated by Rosi, and 68 up-regulated by diabetes and down-regulated by Rosi (Fig. 2, A and B) . Eight genes regulated by diabetes and Rosi were validated by quantitative real-time RT-PCR (Table 3) . Although changes in expression did not consistently reach significance, the trend of downregulation in diabetes and partial normalization with Rosi treatment was confirmed in four of eight genes (Fig. 2C) .
Promoter module enrichment
Groups of functionally related genes regulated in the same direction by diabetes may be under the control of conserved TF binding modules. TFs bind to specific DNA sequences called motifs. Two or more motifs arranged in a consistent order with a consistent spacing in the promoter sequence are designated a TF binding module. Such modules are core features of translation initiation sites. The genes regulated by diabetes identified as either metabolic or mitochondrial by the DAVID functional annotation tool (Table 4) were separated into up-regulated and down-regulated genes. The promoter regions of the DEGs were compared against the Genomatix database of experimentally validated TF modules (www.genomatix.de). Some TF modules were found to be significantly overrepresented or underrepresented in the regulated genes (Table 5) . Results were sorted by the fold change in the frequency of each module in the promoter Hind paw latency, sural sensory NCV, and sciatic motor NCV were not affected by Rosi treatment in control (C) mice (C, C plus Rosi). Panel D, The dityrosine to tyrosine ratio was increased in diabetic mice, and reduced by Rosi treatment. Dityrosine was still increased in diabetic mice treated with Rosi compared with control mice treated with Rosi. E, HODE was increased in diabetic mice and decreased by Rosi treatment. There was no difference between control and diabetic mice treated with Rosi. F, There is a significant correlation between thermal latency and dityrosine ratio. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. 
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Genes significantly regulated in diabetes relative to control were analyzed with the DAVID Functional Annotation Clustering. The table lists the top five nonredundant functional clusters and the median P value of each member of the cluster. The enrichment P value is the probability of finding as many regulated genes in a functional category as were observed, calculated using Fisher's exact test. Because DAVID clusters annotation from over 40 different sources, including GO, KEGG, and Swiss-prot, the median P value from each cluster was used to rank its relative significance. region of these regulated genes compared with the frequency in all promoter regions in the mouse genome. Fold change greater than one is indicative of overrepresentation and a fold change less than one underrepresentation. Modules that are overrepresented in up-regulated genes are likely to have been up-regulated, and vice versa for modules overrepresented in down-regulated genes.
Identifying common TF modules
Common TFs control the regulation of the genes regulated by both diabetes and Rosi. The promoter regions of the two gene groups were searched for conserved TF binding modules using the Genomatix FrameWorker tool. No modules were significantly enriched in the promoter region of genes up-regulated by diabetes and down-regulated by Rosi. A total of 29 novel modules was enriched in the genes downregulated by diabetes and up-regulated by Rosi (P Ͻ 0.05) ( Table 6 ). Genes containing these modules were identified by screening the promoter region of all mouse genes. The GSEA was used to test the hypothesis that these genes are upregulated by Rosi by comparing gene expression levels between control and control plus Rosi mice. The genes containing the SP1F_ZBPF or EGRF_EGRF modules were found to be significantly up-regulated by Rosi treatment (P Ͻ 0.05) (Fig. 3) .
Discussion
DN is a common complication of type 1 and 2 diabetes, resulting from hyperglycemia-induced oxidative stress (29) . The current study evaluated DBA/2J-STZ mice and the effect of Rosi treatment on the development of DN. We found that: 1) the DBA/2J-STZ mice developed DN; 2) Rosi treatment significantly improved thermal latency and reduced oxidative stress in the sciatic nerve; and 3) two novel promoter modules were regulated by both diabetes and Rosi, and are likely relevant to the development of DN.
The DBA/2J-STZ mouse is an established model of type 1 diabetes that develops a profound nephropathy (30) . Using a low-dose STZ protocol, we confirmed diabetes induction and animal survival for 24 wk. The mice were administered insulin to improve long-term survival. The dose was insufficient to restore euglycemia, even when combined with the insulin-sensitizing effects of Rosi. The DBA/2J-STZ mice developed increased fasting blood glucose, GHb, and lost weight relative to control mice, consistent with previous reports (30) . No change in blood glucose, GHb, or weight was observed after Rosi treatment.
DBA/2J-STZ mice developed persistent DN after 24 wk diabetes as measured by both increased thermal latency and decreased NCV. Thermal latency was significantly reduced by Rosi treatment, and NCV studies demonstrated a corresponding trend toward improvement. The discrepancy between these measures may be due to the small effect size of DN on NCV in DBA/2J mice because TZDs have attenuated NCV impairment in STZ-treated Wistar rats (15) . Little is known about the effect of TZDs on peripheral nerve independent of its effect on hyperglycemia in DN. In a model of spinal injury, Rosi significantly reduces damage to both axons and the myelin sheath by a mechanism independent of blood glucose concentration (31) . One factor in this protective effect is likely the reduction of inflammation near the injury site, and correspondingly lower levels of activated microglia and macrophages.
Rosi treatment partially corrected DN but not hyperglycemia, therefore, alternative mechanisms were investigated. To determine whether the amelioration of DN observed is due to a reduction of diabetes-induced oxidative stress, biomarkers of oxidative damage were assayed in the sciatic nerve. Both dityrosine and HODE were significantly elevated in the DBA/2J-STZ mice, consistent with previous work showing that diabetes increases oxidized lipids (32, 33) and protein (34) . Our findings are consistent with the oxidative stress model of DN (29) because thermal latency is highly correlated with increased levels of dityrosine and HODE. Treatment with Rosi reduced both biomarkers significantly, to levels near that of control animals. Because Rosi did not correct hyperglycemia but did reduce oxidative stress, we hypothesize that Rosi promotes antioxidant activity. Several drugs with antioxidant function are effective Gene identifier (ID) is the EntrezGene accession number that uniquely identifies the gene. Fold change is the ratio of the mean expression of the indicated gene in diabetic mice to control mice. Chr, Chromosome; NADH, reduced nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate.
in treating animal models of DN, including the antioxidant response element activator resveratrol (33) and innate antioxidant edaravone (32) . One TZD, troglitazone, is an innate antioxidant, and reduces oxidative stress in a non-PPAR-␥ dependent fashion (16, 35) . The antioxidant capacity is derived from an active chromanol ring, similar to that present in vitamin E (16). Rosi does not have this functional group, and there are no published reports documenting direct antioxidant activity. There is also no evidence that Rosi binds the antioxidant response element. Therefore, we examined the effects of Rosi on gene expression related to its PPAR-␥ agonist activity.
Microarray analyses of the sciatic nerves of the experimental animals found significant and coordinated changes in gene expression due to both diabetes and Rosi treatment. Very little is known about how the hyperglycemic, oxidative diabetes microenvironment alters gene expression in the peripheral nerve, or whether diabetes therapies ameliorate any changes in gene expression. To date, the only microarray experiment performed using diabetic peripheral nerve tissue was performed by Price et al. (36) on the dorsal root ganglia of STZ-treated male Wistar rats. They found that the Gene Ontology categories glucose metabolism, oxidoreductase activity, and manganese ion binding were significantly enriched for regulated genes. The results of the current study are consistent with these findings. Price et al. (36) also reported other enriched categories that we did not reproduce. This may either reflect inherent differences in gene expression between mice and rats and between dorsal root ganglia and sciatic nerve, or it may be due to the more stringent significance criteria in the current study. Gene expression changes that overlap between these two studies are consistent with a model in which hyperglycemia induces neural oxidative stress, and in turn stimulates the expression of compensatory genes in the peripheral nerve.
Common promoter elements among these functionally related, diabetes-altered genes could explain their regulation. The search for metabolic genes regulated by diabetes led to the identification of several well-characterized regulatory elements involved in hyperglycemia-induced changes in gene expression. The most highly up-regulated module, NF1F_NR2F_01, was first identified in the promoter region of pyruvate kinase L (37). The promoter is activated by increased dietary glucose in healthy mice and insulin in diabetic mice, resulting in an expression change of pyruvate kinase L in the liver (38) . High glucose levels in diabetic mice may result in high baseline activity for this module and lead to the observed increase in gene expression of its targets. Therefore, the activation of this module is likely an effect of diabetes, however, its status as a therapeutic target for DN has yet to be defined. Surprisingly, we find that the NFKB_AP1F_01 module is significantly down-regulated in the peripheral nerve of diabetic mice. This differs from previous reports in diabetic nephropathy. Both nuclear factor-B (NFKB) alone (39, 40) as well as NFKB acting in tandem with activator protein-1 (41, 42) are up-regulated in diabetic kidney. However, analysis of NFKB in a peripheral nerve model of DN found no change in NFKB expression (43) . This difference in gene regulation between DN and nephropathy may be one factor that contributes to the different complication profiles of the two tissues. Further study of the tissue-specific function of this module is necessary to understand the effect of its suppression.
Because of the large number of genes regulated between diabetes and control, we only had the statistical power to search for previously characterized promoter modules. By focusing on the smaller set of genes significantly regulated by both diabetes and Rosi, we identified novel promoter modules. Modules with significant sequence homology across the regulated genes were then tested for functional activity by measuring trends in gene expression in the control and control plus Rosi data. These separate lines of evidence identified two promoter modules significantly involved in gene regulation by diabetes and Rosi.
The SP1F_ZBPF binding site is a module that contains binding domains for a stimulating protein 1 (Sp1) family TF and a Krü ppel-like zinc finger TF. The apparent regulation FrameWorker P values are the probability that the binding motif could be found in the promoter region of a set of genes by chance. The module search is performed repeatedly on randomly selected promoter regions to approximate the frequency of matching a promoter sequence by chance. This distribution is the basis for a Z test to determine how likely it is that the genes were found by chance. GSEA P values are the probability that a random gene set could show the same degree of directional regulation as was found in the query gene set. Promoter modules are the experimentally characterized combination of TF binding sites found in the promoter region of the regulated genes. Fold change in frequency is the fold change in the percentage of genes with this promoter module in the regulated genes compared with all mouse promoters. The P value is the probability of finding this degree of change in frequency by chance, calculated using Fisher's exact test.
of this domain is consistent with studies showing that Sp1 is activated by insulin-stimulated glucose metabolism (44) , whereas Krü ppel-like factors are associated with apoptosis, survival, and neurite outgrowth (45) . Although no PPAR-␥ binding motif was found associated with this module, PPAR-␥ stimulates a similar promoter module of Sp1, sterol response element and double E box in mouse adipocytes (46) , independent of a specific DNA binding motif. Sp1 is an intermediate step in the PPAR-␥ induction of resistin (47) and hormone-sensitive lipase (48) , whereas PPAR-␥ suppresses Sp1 expression in a lung carcinoma cell line (49) . Similarly, both TZD (50) and non-TZD (51) activation of PPAR-␥ induces Krü ppel-like-factor 4 in colon cancer cells. Both of the TFs identified in this module have functional associations with diabetes, and both respond to PPAR-␥ activation. These separate lines of evidence support our contention that the SP1F_ZBPF module may constitute a novel therapeutic target in the treatment of DN.
The EGRF_EGRF motif is a double binding site for early growth factors (Egrs) 1 and 2, and similar C2H2 zinc finger factors. A similar artificial motif was used to detect Egr-1 activity (52), lending plausibility to the functionality of this module. In the developing nervous system, Egr-2 mutations are associated with childhood demyelinating diseases (53), and Egr-1 plays a continuing role in the maintenance of the myelin sheath in the adult peripheral nervous system (54) . In the present study, genes with this promoter module are down-regulated by diabetes and up-regulated by Rosi treatment. A non-TZD class of PPAR-␥ agonists, methylene-substituted diindolylmethanes, indirectly activates Egr-1 through a phosphatidylinositol 3-kinase dependent mechanism in prostate and colon cancer cell lines (55) . Conversely, PPAR-␥ inhibits Egr-1 in carbon monoxide-treated macrophages (56), lung tissue after ischemia reperfusion (57) , and in response to spinal cord injury (31) . Although the direction of regulation varies by tissue type and insult, PPAR-␥ clearly affects the expression and activity of Egr-1, consistent with our experimental findings. Our experimental findings and known regulatory association indicate that the EGRF_EGRF module may also constitute a novel therapeutic target in the treatment of DN.
The Genomatix promoter search was limited to cis-acting transcriptional elements to reduce the scope of the searches performed. However, it is possible that regulatory elements more than 500-bp upstream (58) or located in an intron more than 100-bp downstream (59) of the TSS play a significant role in the transcription of these genes. If these promoter modules prove to be insufficiently specific in further exper- iments, it would be necessary to assess the activity of such trans-acting elements more carefully.
In conclusion, this study demonstrates that the DBA/2J-STZ mouse develops and maintains DN. DN is highly correlated with the oxidative stress present in the sciatic nerve, and both are reduced by Rosi treatment. Using a systems biology approach, we found significant changes in gene expression induced by diabetes and Rosi, and that two TF binding modules, SP1F_ZBPF and EGRF_EGRF, are likely involved. These modules constitute novel drug targets and merit future study.
